Dr. Lovell has received honoraria or consulting fees of less than $10,000 from Amgen, Inc. Dr. Solinger has stock ownership or stock options in Amgen, Inc.
Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease
Article first published online: 7 APR 2005
Copyright © 2005 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 52, Issue 4, pages 1283–1286, April 2005
How to Cite
Lovell, D. J., Bowyer, S. L. and Solinger, A. M. (2005), Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis & Rheumatism, 52: 1283–1286. doi: 10.1002/art.20953
- Issue published online: 7 APR 2005
- Article first published online: 7 APR 2005
- Manuscript Accepted: 21 DEC 2004
- Manuscript Received: 28 JUL 2004
Neonatal-onset multisystem inflammatory disease (NOMID) is a rare, childhood-onset disease that is characterized by chronic, systemic inflammation. The purpose of this report is to describe the effects of interleukin-1 (IL-1) blockade on the clinical symptoms of 2 patients with NOMID. At the time of this report, the patients had been treated with anakinra (Kineret), a recombinant human IL-1 receptor antagonist, for 1.5 and 2 years, respectively. Both patients demonstrated rapid improvement in clinical symptoms and laboratory markers of inflammation. The use of anakinra in these patients seemed to be effective, without any safety concerns. These observations suggest that IL-1 plays a critical role in the pathogenesis of this inflammatory disease, and that blockade with anakinra should be further studied as a treatment for patients with NOMID and related disorders.